Belite Bio, Inc
NASDAQ:BLTE
60.18 (USD) • At close April 28, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 7.254 | 6.842 | 9.078 | 6.765 | 4.862 | 8.743 | 5.516 | 5.723 | 5.226 | 1.185 | 1.579 | 0.878 | 1.89 | 1.89 | 1.82 | 1.82 | 1.385 | 1.385 | 0.46 | 0.46 |
| General & Administrative Expenses
| 4.203 | 2.898 | 1.393 | 1.563 | 2.093 | 2.218 | 1.355 | 1.158 | 1.495 | 1.355 | 0.927 | 0.175 | 0.61 | 0.61 | 0.579 | 0.579 | 0.432 | 0.432 | 0.596 | 0.596 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.203 | 2.898 | 1.393 | 1.563 | 2.093 | 2.218 | 1.355 | 1.158 | 1.495 | 1.355 | 0.927 | 0.175 | 0.61 | 0.61 | 0.579 | 0.579 | 0.432 | 0.432 | 0.596 | 0.596 |
| Other Expenses
| 0 | 0 | 0 | 0.463 | -0.085 | 0.027 | 0.062 | -0.008 | -0.07 | 0.137 | 0.115 | -0.017 | 0.032 | 0.032 | 0.032 | 0.032 | -2.872 | -2.872 | -2.872 | -2.872 |
| Operating Expenses
| 11.457 | 9.74 | 10.471 | 8.328 | 6.955 | 10.961 | 6.871 | 6.881 | 6.721 | 2.54 | 2.506 | 1.053 | 2.472 | 2.475 | 2.362 | 2.362 | 1.821 | 1.821 | 1.051 | 1.051 |
| Operating Income
| -11.457 | -9.74 | -10.471 | -8.328 | -6.955 | -10.961 | -6.871 | -6.881 | -6.721 | -2.54 | -2.506 | -1.053 | -2.5 | -2.5 | -2.399 | -2.399 | -1.816 | -1.816 | -1.056 | -1.056 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.357 | 1.061 | 0.977 | 0.463 | -0.036 | 0.027 | 0.062 | -0.008 | -0.063 | 0.137 | 0.115 | -0.017 | 0.027 | 0.027 | 0.039 | 0.039 | -0.005 | -0.005 | 0 | 0 |
| Income Before Tax
| -10.1 | -8.679 | -9.494 | -7.865 | -6.991 | -10.934 | -6.809 | -6.889 | -6.784 | -2.403 | -2.391 | -1.07 | -2.473 | -2.473 | -2.361 | -2.361 | -1.821 | -1.821 | -1.056 | -1.056 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0.006 | -0.001 | 0.001 | 0.003 | 0.006 | 0.033 | -0 | -0.115 | 0.017 | -0.033 | 0 | 0 | 0 | 0 | 0 | 0.001 | 0.001 |
| Net Income
| -10.1 | -8.679 | -9.494 | -7.871 | -6.991 | -10.935 | -6.812 | -6.895 | -6.784 | -2.403 | -2.276 | -1.087 | -2.473 | -2.473 | -2.361 | -2.361 | -1.821 | -1.821 | -1.056 | -1.056 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.33 | -0.28 | -0.31 | -0.27 | -0.25 | -0.4 | -0.26 | -0.33 | -10,436.92 | -0.097 | -0.12 | -0.045 | -0.26 | -0.26 | -0.25 | -0.25 | -0.21 | -0.21 | -0.12 | -0.12 |
| EPS Diluted
| -0.33 | -0.28 | -0.31 | -0.27 | -0.25 | -0.4 | -0.26 | -0.33 | -10,436.92 | -0.097 | -0.12 | -0.045 | -0.26 | -0.26 | -0.25 | -0.25 | -0.21 | -0.21 | -0.12 | -0.12 |
| EBITDA
| -7.579 | -9.74 | -10.436 | -8.293 | -6.955 | -10.945 | -6.855 | -6.865 | -6.705 | -2.533 | -2.499 | -1.046 | -2.492 | -2.492 | -2.392 | -2.392 | -1.812 | -1.812 | -1.052 | -1.052 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |